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As fields become more specialized, ineffective communication between innovators and
practitioners can slow the diffusion of ideas. This paper examines the impact of con-
tinuing education in eating disorder treatment, comparing the take-up of (i) tangible
innovations (psychopharmacology) and (ii) intangible innovations (psychotherapy) fol-
lowing professional conferences. I use a novel extension of an estimator proposed by
Calvi, Lewbel, and Tommasi (2019) in an event study setting to overcome data lim-
itations. I find very small responses among therapists for both kinds of innovations,
suggesting that continuing medical education is not an important channel for treatment
diffusion. Therapists respond more to education in pharmacology than psychotherapy,
being about 3 percentage points more likely to write new prescriptions following a
conference. This increase occurs mainly for adolescent patients being treated by non-
psychiatrist prescribers. Response to purely psychotherapeutic innovations is limited
to more academic-oriented specialists such as psychologists.
Keywords: Mental Health Care , Innovation, Diffusion of Ideas, Classification Error,
Event Study
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1 Introduction
Innovations rest at the heart of many endeavors, and their development, diffusion, and de-
ployment pose critical questions across the spectrum of economic investigation. Generally,
innovations studied in economic models are all treated alike, either as random shocks chang-
ing a technological process, or a simple event disrupting an equilibrium. In these senses,
innovations can be evaluated as though they were policy changes, utilizing many of the
simple causal inference tools popular in the field.
However, a more in-depth study of how innovations are discovered and proceed to sway
equilibria requires an explicit differentiation of innovation types. Some innovations, for
example, are mechanical, such as a software update to a technology that can improve per-
formance for a one-time fixed cost. Others require a more hands-on approach, such as those
that require learning-by-doing (Arrow, 1962) or similar methods. Innovations—like many
other economic objects—are heterogeneous, and can take on a continuum of values in a
potentially high-dimensional characteristic space.
One question that has yet to be asked is how these characteristics affect each innovation’s
success. It is reasonable that innovations with higher fixed costs, more variation in outcome,
or other frictions may diffuse more slowly than innovations with a more straightforward
one-time updating cost. Hence, especially as a landscape of innovation tends to the more
intangible and artisanal, the spread of new ideas in a field may slow, resulting in gaps
between the cutting edge of research and the use of these techniques in practice. Such a
gap—commonly referred to as a research-to-practice gap (RPG)—constitutes an important
problem in many areas of research, including healthcare (Glanz, Rimer, & Viswanath, 2008;
Glasgow & Emmons, 2007; Wandersman et al., 2008) with particular emphasis on mental
health (Jensen et al., 1999; Kazdin, 2011, 2017, 2018; Kazdin, Fitzsimmons-Craft, & Wilfley,
2017). Other important fields investigating RPGs include management practices (Bansal,
Bertels, Ewart, MacConnachie, & O’Brien, 2012; Burke & Rau, 2010; Rynes, Colbert, &
Brown, 2002), education (Coburn & Penuel, 2016; Strohman, 2014), and civil practices such
as social work (Rountree & Pomeroy, 2010).
This project studies a RPG in mental health care. Mental health care is a burgeoning
field of both research and practice, especially as mental health issues become more prominent
in the United States (Olfson, Druss, & Marcus, 2015). Developments in mental health
treatments are typically of two types: pharmacological (e.g., new drugs) or therapeutic (e.g.,
new models of psychotherapy). My aim is to exploit the differences in these innovations to
examine a potentially differentiated rate of innovation take-up among practitioners. I exploit
quasi-random attendance of professional trainings (in the form of professional conferences)
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in both psychotherapy and psychopharmacology among mental health professionals, and
assess the impact of each. I implement a panel event study design to assess changes in
treatment patterns for therapists who are most likely to attend professional conferences in
eating disorder treatments. I explore potentially differentiated responses by provider type
and patient demographics, and conclude with an exploration of potential mechanisms for
these responses and a validation of my treatment assigning algorithm.
I find muted response among mental health professionals to either kind of professional
conference. While this may be the result of an overtaxing estimation process, it provides
some suggestive evidence that continuing medical education is not the driver for changes in
the treatment behaviors of therapists. Therapists did increase their use of olanzapine (an
atypical antipsychotic occasionally prescribed for eating disorder treatments, discussed more
in Section 2.2). Interestingly, this response occurred only among non-psychiatrists (e.g.,
psychiatric nurse practitioners) and was used on adolescent patients. However, therapists
did not have a similar response to therapeutic education; in fact, when exploring the over-
all variation in a provider’s treatment profile, I find suggestive evidence that a conference
discourages experimentation.
For clarity, in this paper I make the (somewhat informal) distinction between tangible and
intangible innovations. Tangible innovations are algorithmic in nature: while they may re-
quire specific skills and training to be able to implement, their implementation requires little
creativity and varies little across implementations and practitioners. Many of the innova-
tions that come easily to mind—new drugs, medical equipment, etc.—fall into this category.
In contrast, intangible innovations depend more heavily on human capital, and therefore can
vary widely based on who is implementing it (or even across cases with the same practi-
tioner). The example of intangible innovation used in this project is psychotherapy, which is
a rigorous and scientific medical treatment, but also requires a conscious cultivation of rela-
tionship between therapist and patient that is impossible to achieve algorithmically. While
new therapeutic techniques can be proposed and validated by mental health researchers,
the passing on of these guidelines from researcher to practitioner will inevitably leave room
for practitioners to adapt the practice to their own treatment style, potentially altering the
benefits of the development. Other examples of intangible innovations in health care include
testing and prescription guidelines (Mullainathan & Obermeyer, 2019), as well as any other
behaviors subject to clinician interpretation.
Of course, this distinction is a simplifying one, as nearly all innovations contain elements
of both “art” and “science”. For example, Graham, Lattie, and Mohr (2019) discuss the im-
plementation of new digital mental health technologies, an ostensibly algorithmic innovation
(e.g., a cell phone application) that requires specialist understanding of the mechanisms at
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play in order to be successfully integrated into a treatment plan. While elements of arti-
sanal and algorithmic innovations exist in almost every development (particularly in a field
such as mental health), I have attempted to choose two key innovations that are as close to
purely tangible and intangible as possible: psychotropic medication and psychotherapeutic
techniques.
The contributions of this study are both methodological and practical. First, this study
proposes a way to point identify dynamic treatment effects even in the presence of clas-
sification error. This extension of recent work (most notably, Calvi et al., 2019) increases
researchers’ flexibility to answer causally motivated questions in the presence of limited data,
as well as suggesting ways predictive algorithms (such as machine learning techniques) could
be used in causal designs. In addition, this paper discusses how an interpretation of these
results might change when the necessary assumptions are implausible or hold only partially,
and outlines how validation samples can be used to test the necessary assumptions.
The factors and frictions affecting technology diffusion is a central question in economics—
and health economics in particular—and this paper contributes to this rich literature by
assessing diffusion under heterogeneous take-up costs on the innovation side. Recently, this
literature has been concerned with proposing explanations for heterogeneous rates of innova-
tion take-up; these solutions explore factors such as differences in social network structures
(Arieli, Babichenko, Peretz, & Young, 2019), the presence of network effects (Ackerberg
& Gowrisankaran, 2006), and variations in take-up costs among potential users (Ryan &
Tucker, 2012). However, each of these projects considers only one innovation at a time in or-
der to prioritize demand-side heterogeneity (Young, 2009). In contrast, the current project
examines how different innovations—with potentially varying take-up costs—compete for
takeup among practitioners. The current setting allows for identification of reduced form
evidence exploring the ways these costs drive differences in take-up within a specific clinical
population (mental health professionals).
From a clinical perspective, this project also contributes to a broad discussion on gaps be-
tween research and practice by highlighting one of the most common frictions in the diffusion
of ideas: communication. Some papers find strong responses of medical professionals to ran-
domized trials (Depalo, Bhattacharya, Atella, & Belotti, 2019), but the dissemination of this
information is not always straightforward (Casper, 2007; Grimshaw et al., 2001). Continuing
education is the most common method by which medical professionals receive information
about new medical research (Church et al., 2010). However, as even medical conferences
become more specialized, tailored either to academics1 or professionals, continuing educa-
1For example, the Eating Disorders Research Society holds an annual conference limited only to its
members. As a result, only academics attend, not professionals.
3
tion has the potential to devolve into a “blind leading the blind” environment, where the
trainers are as removed from medical research as the trainees. This, and many other factors,
warrants an evaluation of continuing education as a potential source of research-to-practice
gaps. This study contributes not only to a discussion on the uses of continuing education,
but also a much larger literature on innovation diffusion in intangible settings.
Finally, this paper is also tangentially related to a burgeoning literature on the diffusion
of ideas, a discussion on how intangible goods such as international ideals (Gilardi, 2012)
and social movements (Rane & Salem, 2012). For example, Ash, Chen, and Naidu (2019)
examine the spread of economic language among judges following a training program. Their
particular type of policy evaluation (with dynamic treatment effects) is similar to the aims
of this paper.
2 Background & Data
The diffusion of innovation into practice is a central issue for nearly every area of technolog-
ical advancement. In simple cases, standard economic models predict that technologies that
increase marginal benefit or decrease marginal cost will have quicker take-up by practitioners,
becoming a new norm until further innovation disrupts the equilibrium again (Christensen,
Baumann, Ruggles, & Sadtler, 2006; Christensen, Grossman, & Hwang, 2009; Christensen,
Raynor, & McDonald, 2015). However, in the presence of frictions, the diffusion of innova-
tions may depend on much more than their simple benefit/cost contributions, and standard
models may be insufficient to predict how a field will develop. This is particularly true when
innovations are intangible in nature, as this makes them particularly vulnerable to frictions.
2.1 Research to Practice Gaps
One friction that is particularly salient in the diffusion of intangible medical innovation is
a growing divide between academics and professionals (Kazdin & Blase, 2011; Kazdin et
al., 2017). With increasing specialization, a burgeoning field such as mental health care
becomes split into two camps: one performing and reporting the results of clinical trials and
other research, and a second that interprets and incorporates these results as they treat real
patients. However, as this specialization progresses, the distance a new idea must travel
from the laboratory to the patient increases, raising the chances that it will either not be
adopted, or adopted in some stunted capacity.
Communication between these two groups—especially in the medical profession—is in-
centivized through continuing medical education (CME) programs for practitioners. These
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programs are motivated by the documented fact that physicians who have been practicing
longer tend to stall in updating their practices, putting them at risk for delivering lower-
quality care (Choudhry, Fletcher, & Soumerai, 2005). While the structure of CME programs
tends to vary across states and facilities, a typical curriculum generally requires a mix of
completing courses taught by state-approved providers, preparing and teaching courses to
other professionals, and presenting at professional conferences, with additional options for
research, publications, or media involvement. Licensures may be awarded following the com-
pletion of certain milestones in a CME program, allowing a mental health professional to
advertise as “licensed” in an attempt to increase demand.
In recent years, CME programs have evolved to allow online learning through approved
online classes, webinars, and presentations. This has been done largely to reduce the burden
continuing education places on rural physicians (Curran, Fleet, & Kirby, 2006) and improve
access more generally. In fact, Hugenholtz, de Croon, Smits, van Dijk, and Nieuwenhuijsen
(2008) have demonstrated that online continuing education is just as effective as traditional,
in-person lectures. Despite this, most states still require at least some continuing education
to be done in person. Because of this, professional conferences continue to be hubs for
continuing education presentations, exams, and courses.
The potential benefits for professional conferences are inherent in the nature of the event,
and tend to be highly favored by practitioners (Dysart & Tomlin, 2002). In fact, according
to Dysart and Tomlin, professional conferences are attended with about the same frequency
as all other continuing education events combined;2 however, their work also highlights
the difficulties associated with receiving education through expensive and travel-intensive
methods such as conference attendance. Healthcare facilities are rarely generous in providing
time off for conference attendance, and conference and travel fees are typically borne by the
provider rather than the employer.
2.2 The Case of Eating Disorder Treatments
In an attempt to assess the quality of communication and training in inducing innovation
takeup, the current project examines continuing education on practices in the treatment of
eating disorders. These mental disorders centered around unhealthy relationships with food
and eating. They include anorexia nervosa, typified by body dysmorphia and severe restric-
tion of food intake; bulimia nervosa, characterized by purging excessive food consumption;
binge eating disorder, a disease marked by superfluous food consumption (but no purging);
and other unspecified diseases. This study will focus on patients with diagnoses of either
2Their study examined occupational therapists, rather than mental health professionals.
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anorexia nervosa or bulimia nervosa exclusively.3
These diseases are ideal for the current study for three principal reasons. First, these
diseases have the highest mortality rate of any mental illness (Arcelus, Mitchell, Wales, &
Nielsen, 2011), making them a pragmatically relevant area of focus. Second, treatment of
eating disorders involves both algorithmic and intangible processes: for example, the refeed-
ing process of severely malnourished anorexic patients is medically more straightforward
than the psychotherapeutic aspects of treatment. However, as discussed in more detail be-
low, many of the algorithmic treatment methods—such as pharmacological treatments—have
much weaker empirical support than psychotherapies. Hence, in the absence of a research-
to-practice gap biasing treatments towards algorithmic interventions, one should observe the
use of intangible treatments (e.g., psychotherapy) dwarfing the number of pharmacological
interventions. Finally, the study of eating disorders meshses well with available data. While
it is a myth that they affect only female adolescents from the middle- and upper- classes
(Mitchison, Hay, Slewa-Younan, & Mond, 2014), a substantial number of those suffering
from this disease will have private insurance. Additionally, there are easily identifiable diag-
nosis codes for each eating disorder and treatment codes for the two treatments of interest
(family-based therapy and olanzapine prescriptions, discussed below). Therefore, I have a
clean identification of the populations and outcomes of interest.
While treatment patterns vary for each individual patient, treatment of eating disorders
is recommended to follow a team-based model of care (American Psychiatric Association,
2006), with the team generally comprised of a principal psychotherapist, a dietitian (and
other general medicine professionals if needed to deal with secondary effects of the disor-
der), a psychiatrist, and occassionally a social worker. Treatment proceeds in stages, with
early stages focused on rectifying any secondary effects of an eating disorder (e.g., a re-
feeding or rapid weight gain process), and later stages focusing on mental health treatments.
Hospitalizations—if any are required—typically take place in the first stages, with the latter
stages largely taking place in an outpatient setting. It is this latter, mental health-oriented
stage, with which this project is concerned. This stage typically consists of two major treat-
ment modalities: psychotherapeutic and psychopharmacological.
Family-based therapies (FBT) are considered an optimal therapeutic intervention for the
treatment of anorexia nervosa, bulimia nervosa, and eating disorders not otherwise specified
(Loeb, Lock, Greif, & Le Grange, 2012). In this treatment, family members of a patient are
integrated into a team of health professionals, as opposed to other psychological practices,
which at best ostracize family members and at worst paint them as responsible for mental
3Note that binge eating disorder did not have its own diagnosis code until the release of the ICD-10-CM
Diagnosis Codes, which were used beginning in October 2015 (after my sample started).
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illnesses (Le Grange, Lock, Loeb, & Nicholls, 2010). FBT, developed at the Maudsley hos-
pital in London by Dare and Eisler (2000) and manualized for anorexia nervosa by Lock and
Grange (2015), currently boasts the strongest empirical support of any psycho-therapeutic
intervention for treating anorexia nervosa, including hospitalization.4 The two most recent
meta-analyses—Couturier, Kimber, and Szatmari (2013) and Bulik, Berkman, Brownley,
Sedway, and Lohr (2007)—each conclude that family-based treatments are more efficacious
than many routine treatment methods, particularly for adolescents and youth. Importantly,
the advantages of FBT are most notable in the long-term, with positive impacts 6–12 months
after treatment that outweigh even the benefits of individual cognitive-based therapy (Cou-
turier et al., 2013). As these authors write:
“Family therapy focusing on symptom interruption of eating disordered behav-
iors should be recommended as the first line of treatment for adolescents with
eating disorders. Given the growing evidence base for FBT for adolescents with
eating disorders, it would be prudent to study implementation strategies and
effectiveness of this treatment in the community.” (Couturier et al., 2013)
Family-based therapy is recommended by the American Psychiatric Association (Ameri-
can Psychiatric Association, 2006) and the National Institute for Health and Care Excellence
in the UK (for Health and Care Excellence, 2017) as the main intervention for eating dis-
orders. Despite this, however, the overall use of FBT in eating disorder treatments in the
outpatient setting remains consistently low. Figure 1 shows the percentage of all eating disor-
der patients in the MarketScan data receiving any form of family-based treatment over time.
The graph shows that only around 15% of the 23,000 patients in the sample (and around 26%
of the 10,000 youth and adolescent patients) ever receive FBT in their treatment. Further-
more, the graph shows the publication dates of major RCTs and meta-analyses positively
evaluating FBT, with little implied physician response shown as a result. This suggests that
providers may already have sorted into those who provide FBT to their patients and those
who do not, and that the current stream of ongoing research does not affect their decision
to provide this treatment.
Of course, FBT will not be ideal for every eating disorder patient. Factors such as family
instability, need for longer treatment, and co-morbid psychiatric disorder may influence a
patient’s lack of response to FBT (Lock, Couturier, Bryson, & Agras, 2006). Additionally,
FBT has been proven more useful for adolescents than adults (Bulik et al., 2007). Finally,
some specialists are able to use family-based techniques across a wide range of diagnoses out-
side of eating disorders; this may incentivize certain mental health practitioners to specialize




Therapist Response to Publications on Family-Based Therapy
in a family-based approach, allowing specific patients to seek out this treatment modality if
they feel it may be a good match for their needs.
The second major treatment modality for eating disorders is pharmacological; however,
the evidence base for this style of treatment is scant relative to that of therapeutic techniques.
There are only two FDA-approved medications for eating disorder treatments: fluoxetine for
bulimia nervosa (approved in 1994) and vyvanse for binge eating disorder (expanded approval
to BED in 2015), both of which suppress purging behaviors. Additional medications—
particularly SSRIs or other antidepressants—are typically prescribed to assist in mitigating
co-morbid depression and/or anxiety symptoms (American Psychiatric Association, 2006).
Overall, there are no good pharmacological treatments to handle a patient’s relationship
with food, making the therapeutic treatment arm essential.
Even without empirical support, an increasing number of prescribers have begun en-
gaging in off-label experimentation in the treatment of eating disorders (Maglione & Hu,
2011). Much of this experimentation uses atypical antipsychotics—which are FDA approved
and typically prescribed for schizophrenia and bipolar disorder—to manage weight gain.
For example, olanzapine (the most commonly prescribed atypical antipsychotic for eating
disorders) is known to induce weight gain as a common side effect, and hence has been
viewed as potentially useful in anorexia nervosa treatments (Flament, Bissada, & Spettigue,
2012). While there have been some studies examining these medications (see Maglione and
Hu (2011) for a meta-analysis), there is not enough conclusive evidence that these medica-
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tions are effective in treating eating disorders to warrant a change in their FDA approval
status presently; however, continuing education and professional conferences still include
discussions of incorporating off-label drugs into psychopharmacological practice in an ED
treatment profile.
2.3 This Project
This project focuses on a single potential friction between academic research and practice:
the impact of professional education. Specifically, I focus on the implementation of FBT
and prescription of olanzapine in eating disorder treatments, two innovations that embody
different styles of innovation and may thus diffuse differently. The prescription of olanzap-
ine, while an off-label practice with relatively little empirical support, has a straightforward
implementation, and constitutes a more algorithmic innovation. However, the use of family-
based therapies requires specialists to provide a higher level of care, and its implementation
therefore varies widely across therapists, in keeping with intangible innovation. This het-
erogeneous implementation of FBT in eating disorder treatments has been documented in
Kosmerly, Waller, and Robinson (2015).
To evaluate this takeup, I use a list of about 70 conferences targeted at eating disorder
professionals and clinicians. For each conference whose online program is available, I am able
to ascertain if the conference ran any sessions or presentations on either FBT or olanzapine
use in ED treatments, as well as creating a registry of the conference locations and times.
Table 1 shows the organizations and conferences examined. Aside from conferences whose
programs are not available, I have the universe of such professionally-oriented conferences.5 I
couple this with a sample of 4,476 therapists and professionals from the Truven MarketScan
data to examine treatment profiles of specialists before and after conference attendance.
The main complication is that I have no data on who actually chose to attend each
conference;6 instead, I will estimate treatment status based on each specialist’s cost (in
travel) of attending a conference. By assuming that therapists are more likely to attend
conferences that are low-cost to them, I am able to artificially assign specialists to treatment
and control groups, as discussed in more detail in Section 3.1. Finally, I extend recent
work on dealing with classification error in treatment effect models (Calvi et al., 2019) to
approximate the local average treatment effect of attending these conferences.
Hence, this paper provides two distinct contributions. The first is methodological in
5Note that this excludes academic conferences which are limited to members of the academic organization
only (for example, the Academy of Eating Disorders) as not all clinicians would have the opportunity to
attend.
6Note that I have data on conference registration for a few conferences, which I will use in a validation
exercise in Section 5.
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Table 1
Professional Conferences on Eating Disorder (ED) Treatments Examined
Organization Conference Name Frequency Total
Programs
FBT Olanzapine
Academy for EDs International Conference
on ED
Annual 9 7 4
American Academy of Child &
Adolescent Psychiatry
AACAP Meetings Annual 10 2 4
Annual Eating Recovery
Foundation
ERF Conference Annual 3 3 0
Center for Change National ED Conference
for Professionals
Annual 5 1
International Association of ED
Professionals
IAEDP Symposium Annual 9 6 2
Maudsley Parents One-Day FBT Conferences Sporadic 3 3 0
Multi-service ED Association MEDACon Annual 3 2 1
National ED Association NEDACon Annual 4 3 0
Renfrew Center Foundation Conference for
Professionals, Seminar
Series
Annual+ 15 8 0
Center for ED at Sheppard Pratt Professional Symposium Annual 6 3 0
Summit for Clinical Excellence National ED Conference Sporadic 4 1 1
UCSD ED Treatment Center Trainings for Professionals Sporadic 2 1 0
Total: 73 40 12
1. Abbreviations: ED = eating disorder; AACAP = American Academy of Child & Adolescent Psychiatry; ERF =
Eating Recovery Foundation; IAEDP = International Association of Eating Disorder Professionals; FBT = Family-
based therapy; UCSD = University of California at San Diego.
nature, and presents a toolkit of econometric techniques to assist researchers in overcoming
data limitations. Specifically, this paper introduces an instrumental variables technique for
the event study approach, integrates predictive algorithms into a causal framework, and
extends results that adjust these frameworks for classification errors. Due to the reasonably
complicated procedure by which my results are derived, several sections of this paper are
dedicated to the exposition of the algorithm and intuition behind its use.
Secondly, I present information detailing how medical professionals respond to contin-
uing education in the form of professional conferences. I argue that these responses are
potentially differentiated on the basis of which techniques or tools are being discussed, and
examine heterogeneity by audience (specialist type) and population of interest (patient de-
mographics). Ultimately, the results of this exercise provide little evidence that continuing
education changes behavior in the aggregate, either for intangible or algorithmic innovations
(psychotherapy and prescriptions, respectively). This finding warrants future research in
light of the severe data limitations and complex econometric procedure, which is taxing for
the available data; however, if true, this finding suggests a need to better understand the
optimal way to transmit information to practicing professionals.
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3 Empirical Design
Dynamic treatment effects are at the heart of questions surrounding innovation adoption. I
am ultimately interested in how professional conferences impacted the use of FBT and olan-
zapine over time for each specialist who attended. I have concrete data on each specialist’s
treatment profile for their subset of patients who are covered by an insurer in the MarketScan
database; however, I do not have reliable data on conference attendance for these physicians.
My empirical approach will (i) estimate treatment status for each medical professional and
conference, (ii) estimate a dynamic treatment effect of professional education using an event
study framework, and (iii) adjust for potential classification error in the first step.
This project combines various econometric approaches to attempt point identification of
my dynamic treatment effect of interest. To fill in data gaps, I employ a predictive algorithm
that infers who attends each conference; this suggests a place for more sophisticated machine
learning techniques in causal research designs. To deal with the flaws inherent in any such
algorithm, I extend an estimator that is robust to measurement error in a treatment variable
to an panel event study framework.7 Using this estimator in tandem with a transformed IV
approach allows me to approximate a Dynamic Local Average Treatment Effect (D-LATE)
for the specialists in my sample who are induced to take-up treatment (the compliers).
Event study designs have become increasingly popular in recent years (see Abraham and
Sun (2018); Borusyak and Jaravel (2017); and de Chaisemartin and D’Haultfoeuille (2019)
for important reviews on the subject). These designs rely on variation in treatment time
(with or without the presence of a control group to explore treatment effects in periods both
leading up to and following the treatment period, as well as the presence of a control group
to correctly control for time fixed effects (Hull, 2018). This design can flexibly be used to
explore heterogeneous responses in an appealing way when the number of groups to compare
is relatively small, as in Johannesen and Stolper (2017).
3.1 Estimating Treatment Categories
While my data are ideally suited for the study of a medical professional’s treatment profile,
they contain no information on continuing education or conference attendance. Hence, I
use a predictive algorithm to infer each specialist’s decision to attend a CME conference
based on their travel costs. The algorithm is based off of the assumption that given that
opportunities for continuing education are nearly ubiquitous, decisions to attend conferences
for professionals will be driven largely by costs: an ED specialist in Boston is far more
7The Mismeasurement Robust LATE Estimator of Calvi et al. (2019), discussed in more detail in Section
3.3.1.
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likely to attend conferences when they are held in New England than when they are held in
California.
Details of this algorithm are relegated to Appendix B for brevity. In general, for each
mental health specialist and each conference, I compute a measure of travel cost taking
into account both the physical cost of travel and the opportunity cost of time. From this
continuous measure, I infer a treatment group as the smallest η-percentile of specialists
when ranked by their travel costs. This move from a continuous variable to a discrete one is
motivated by the classification error framework laid out in the next subsection; by varying
this threshold I change the probabilities of misclassifying a treated/control therapist in a
near-monotonic fashion.8 This is useful for the assumptions of the MR-LATE estimator
discussed in Section 3.3. However, future research might explore the potential use of this
continuous measure in a propensity-weighting framework, as well as how such a framework
compares to that of Calvi et al. (2019). Additionally, future research could integrate more
sophisticated machine learning techniques to improve prediction accuracy, providing a better
approximation of the true LATE (as discussed in Section 3.3).
Figures 2 and 3 show an example of the algorithm’s output for a sample conference for
professionals that took place in September 2012 in Boston. Figure 2 shows the estimated
travel cost to attend the conference for each specialist in the sample at that time, while
Figure 3 shows the estimated distribution of travel costs, including various cities as reference
points. Specialists in cities farther away from Boston incur greater travel costs to attending
the conference, but those in distant rural areas (such as Mountain Home, Idaho) incur
even greater travel costs. By selecting the lowest η-quantile of the distribution, different
treatment groups are created, with differing levels of austerity in selecting the treatment (or
control) groups9. Notice that these treatment groups are not merely centered around the
conference location—indeed Atlanta, Georgia, which is a hub for major airlines, has a lower
travel cost to a Boston 2012 conference than does New Haven, Connecticut. This illustrates
that incorporating travel costs into the predictive algorithm may provide an improvement in
prediction quality over a simple geographic distance calculation.
When repeated for all conferences, this procedure creates estimated treatment groups for
each of the conferences in the sample (40 conferences for FBT trainings and 12 for olanzapine
prescriptions). In order to conduct an event study analysis, it is important that treatment
be an absorbing state for each therapist;10 hence, each therapist is assigned a treatment date
8That is, as η increases, I tend to increase the probability of classifying a control therapist as being
treated, while decreasing the probability of classifying a treated therapist as part of the control group.
9The red line in Figure 3 illustrates a treatment group based on the lowest 10% of travel costs.
10That is, each specialist ought to be treated only once, and remain treated throughout the duration of
the sample after that.
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Figure 2
Estimated Travel Cost for all Specialists, Boston 2012 Conference
as the earliest time period for which it is estimated that they attended a conference on FBT
or olanzapine. From this estimated treatment time, relative time dummies typical for an
event study are created, completing the necessary data configuration.
3.2 Instruments in Event Study Designs
While the use of instruments in an event study is rare compared to their prevalence in other
empirical designs, the generalization from the instrumented difference-in-differences design
(DDIV) to an instrumented event study design (ESIV) is straightforward. As explained in
Hudson, Hull, and Liebersohn (2017), the basic model for the DDIV is Equation 1:
yit = αi + τt + βDit + εit, (1)
where αi and τt represent individual and time fixed effects, and Dit is the binary (potentially
endogenous) treatment status.11 To deal with the endogeneity of treatment Dit, a binary
instrument Zit is used.
The event study framework generalizes this by mapping between a single treatment
indicator Dit and a vector of relative time dummies, which indicate how much time has
elapsed since the treatment event. For each individual i in a panel, the event is denoted as




Estimated Distribution of Travel Cost for all Specialists, Boston 2012 Conference
Ei = mint{Dit = 1}; given this, each period t can be assigned a value Kit = t − Ei. This
essentially re-orders the time periods in a panel so that each individual appears to have been
treated simultaneously. Once this is complete, the estimating equation can be written as
Equation 2
yit = αi + τt +
∞∑
k=−∞
γk1 {Kit = k}+ εit. (2)
In this setup, each parameter γi indicates the effect of the treatment event on the outcome
variable i periods before or after the event itself. See Borusyak and Jaravel (2017), de
Chaisemartin and D’Haultfoeuille (2019) for a more detailed discussion of the event study
approach. Generally, applied researchers do not estimate the fully dynamic specification
(where k ranges over all integers), but limit k ∈ [−A,B] for two positive integers A and
B12. This establishes the vector parameters (γ0, γ1, ..., γB) as the parameters of interest
(sometimes referred to as the dynamic treatment effect parameters).
Suppose now that there exists a valid instrument Zit for Dit. To transform this instrument
to be a valid one for the event study approach, one need only follow the same procedure
outlined above: for each individual i, define the instrumented event Z ′i as the point that is
most likely to induce the treatment event, then define the relative time periods Z ′it = t−Z ′i
12For identification, such an approach requires omitting a dummy as a reference group, which is typically
chosen to be γ−1.
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as before. Given that Zit is correlated with Dit, the transformed instrument Z
′
it will be
correlated with Kit, ensuring that the procedure is valid.
My main instrumental variable is the presence of a “slow spell” for a therapist in the
months leading up to a conference. Specifically, if a specialist’s average patient volume 4–6
months prior to a conference is lower than their overall average volume, the binary instrument
is given a value of 1 (and 0 otherwise). By indicating a potential decline in patients treated
during a registration period for a conference, I hypothesize that this instrument will be
positively correlated with true conference attendance. Additionally, since such a measure
is uncorrelated with both (i) distance between therapist and conference and (ii) therapist
treatment profiles, this measure is a valid instrument for the treatment. I therefore define
Z ′i as the period with the lowest measured lagged patient volume for each specialist i.
3.3 Dealing with Classification Error
Given that I infer treatment status based on an imperfect proxy (travel costs), dealing with
classification error is a first order concern in my estimation approach.13 There is a small, but
vibrant, literature on dealing with classification errors in applied microeconometric models.
The most notable of these papers, Lewbel (2007b) point identifies the average treatment
effect (ATE) in a simple treatment effects model. Other important papers extend this result
to include covariates or discretized treatment levels (Hu, 2008; Lewbel, 2007a; Mahajan,
2006). Most recently, these researchers have turned to the problem of estimating Local
Average Treatment Effects (LATEs) in the presence of potentially endogenous selection
into treatment. This paper extends the recent work of Calvi et al. (2019), who identify a
mismeasurement-robust estimator of the LATE (the MR-LATE) used for bias reduction in
classification error problems.14
3.3.1 The MR-LATE Estimator of Calvi et al. (2019)
Calvi et al. (2019) propose an estimator that is “mismeasurement robust” in the sense that
it can approximate the LATE under weak assumptions. In their framework, there is a true
treatment status D ∈ {0, 1}, which is unobserved and cannot be consistently estimated. In
13Classification error refers to measurement error in a variable denoting treatment status. Ignoring this
error—which by construction is nonclassical—can lead to serious problems in estimating a treatment effect,
as discussed in detail in Millimet (2010). Kreider (2010) shows that even in a case of infrequent classification
error—from 2% or less—can result in estimated effects whose confidence intervals do not overlap the true
treatment effect, and may even suggest the opposite sign of the true ATE.
14There is another recent paper that tackles this issue (Yanagi, 2018), but this requires additional as-
sumptions and applies to a more restricted class of circumstances.
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addition, there exists a binary instrument Z such that the typical LATE assumptions of
imbens˙identification˙1994 are satisfied (as replicated in Assumption 1).
Assumption 1: LATE Assumptions. The outcome Y and true treatment status D,
together with a binary instrument Z satisfy:
i. 0 < E[D] < 1, 0 < E[Z] < 1, and Z⊥(Y1, Y0, D1, D0).
ii. (Y1, Y0, D1, D0, Z) are independent across individuals and have finite means.
iii. There are no defiers, hence P(D0 = 1 ∩D1 = 0) = 0,
where subscripts are indicative of potential outcomes following the typical framework.
While D cannot be consistently estimated, it is approximated by two imperfect measures
T a, T b ∈ {0, 1}. These measures satisfy an extended set of the LATE assumptions in As-
sumption 2 (where compliers are denoted by C):
Assumption 2: Mismeasured LATE Assumptions. T i is such that the following
conditions are satisfied for i ∈ {a, b}:
i. Z⊥(Y1, Y0, D1, D0, T i1, T i0).
ii. (T i1, T
i
0)⊥(Y1, Y0)|C.
iii. E[T i1 − T i0|C] 6= 0.
That is, in addition to the typical unconfoundness assumption, Assumption 2-i assumes
the instrument is independent of the potential measurement errors in T i. The second part
of the assumption indicates that the potential outcomes of each mismeasurement are in-
dependent of the potential outcomes of the dependent variable Y ; combined with the first
assumption, this asserts that any measurement errors are uncorrelated with outcome vari-
ables. Finally, Assumption 2-iii requires only that T provide some information about D.
Given these two assumptions, Calvi et al. (2019) apply the reasonable well-known fact
that a transformed two-stage least squares (2SLS) regression of Y T on T (using Z as the
instrument) can be written as a mixture of the potential outcomes for compliers:
Cov(Y T i, Z)
Cov(T i, Z)
=
E(Y T i|Z = 1)− E(Y T i|Z = 0)
E(T i|Z = 1)− E(T i|Z = 0)
(3)
= E [qY1 + (1− q)Y0|C] , (4)
where q is a weight related to the probability of measurement errors in T given true treatment
D. Given this result,15 Calvi and coauthors define the MR-LATE estimator as the difference
15This result is not unique to Calvi et al. (2019), but has been mentioned in earlier work, including Abadie
(2002) and Ura (2018).
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in two 2SLS estimators, given the two mismeasured treatments T a and T b:







Using this definition and the result from their first theorem (Equation 4), it follows
immediately that the MR-LATE is a multiple of the LATE, with the weighting (qa − qb);
Hence, the MR-LATE is equal to the true LATE when (qa − qb) = 1. A sufficient condition
for this to hold is that of Assumption 3:
Assumption 3: Sufficient Condition for MR-LATE = LATE. T a and T b are such
that the following two conditions are met:
i. pa0 = 0. That is, among compliers, the mismeasured treatment T
a never mistakes the
actually untreated as treated.
ii. pb1 = 0. That is, among compliers, the mismeasured treatment T
b never mistakes the
actually treated as untreated.
These restrictions—that one treatment group is strict in its definition of the treatment
group, and the other in its definition of the control group—are related to the no-defiers
assumption typical in a LATE framework. By eliminating certain combinations of D and
Z, the no-defiers assumption allows for a clean interpretation of the local average treatment
effect. In a similar vein, Assumption 3 rules out certain types of measurement errors, thereby
eliminating extraneous cases wherein the MR-LATE would be different from the true LATE.
As in cases where the no-defiers assumption is violated, an MR-LATE estimator approx-
imates the LATE in cases where Assumption 3’s conditions are nearly met (meaning that
qa − qb is close to one). Judging the extent to which the conditions of these assumptions
are met is typically impossible given the limitations of the data; however, I have obtained
actual conference registration data from recent ED conferences held by the Academy for
Eating Disorders, which I use as a validation sample in Section 5. With this new data, I am
also able to address concerns about a lack of strong identification arising from an imprecise
treatment group estimation.
3.3.2 This paper: The Dynamic LATE (D-LATE) Estimator
Extending Lewbel’s work to the event-study setting is relatively straightforward. Theorem
1 below restates the necessary setup and assumptions for the MR-LATE to be identified for
each parameter βi of the dynamic treatment effect.
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Theorem 1 Let {Y,D,Z, T a, T b} be such that Assumptions 1 and 2 are satisfied. Consider
estimating an instrumented event study regression (equation 2) on the transformed variable
T iY using T as the treatment measure and Z as the instrument. Then, for any time period
t relative to the treatment period, the dynamic treatment coefficient γt satisfies
γt = E[qY1 + (1− q)Y0|C], (5)
for a q related to the probability of mismeasurement in the substitute treatment measure T i.
See Appendix A for a proof of this theorem. This extension of the theorem relies on two
facts: first, that an event study design is simply a transformation of the DDIV estimator
into one with many dummy variables, as discussed in 3.2. Hence, estimating a LATE model
with one instrument is equivalent to estimating a corresponding ESIV model with many
instruments (one for each dummy). Second, as discussed in Angrist and Imbens (1995),
coefficients in two-stage least squares models with multiple instruments can be written as a
linear combination of each instrument-specific LATE.
Given the results on Theorem 1, the corollary of Calvi et al. (2019) immediately implies
that a dynamic version of the MR-LATE (which I call the dynamic MR-LATE or D-LATE
for short) is equivalent to the true LATE under the conditions stipulated in Assumption 3.
Hence, in order to resolve issues of classification error while still obtaining a dynamic treat-
ment effect, I use two measures of treatment status—one that never misclassifies the treated,
and another that never misclassifies the untreated—and the quasi-randomized instrument of
patient volume during the conference registration period, as discussed in Section 3.2.
For the two mismeasured treatment estimates, I can use the travel cost algorithm de-
scribed in the preceding subsection with varying thresholds. That is, I create two estimated
treatment groups for each conference, one with a very strict threshold for attendance (e.g.,
only the lowest ventile of travel costs) and one with a very liberal threshold (e.g., the 95th
percentile of travel costs). In this way, I ensure that one of the mismeasured treatments is
unlikely to mistake a truly treated professional as a control member, and the other is unlikely
to make the opposite mistake, thereby at least approximating the sufficient conditions for
the D-LATE estimator to be equivalent to the LATE.
I therefore obtain estimates and standard errors of the D-LATE using the following
procedure. First, I estimate two event study regressions (using equation 2) using T iY as the
dependent variable, T i as the treatment status (that determines the dummy variables), and
Z as the instrument. The MR-LATE estimator for each coefficient of interest γi is given by
γMRi = γ
a
i − γbi . Finally, I obtain bootstrapped panel errors for each coefficient use the panel
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bootstrap method.16
4 Estimation Results & Heterogeneity
The D-LATE estimator was implemented to evaluate two sets of professional conferences: one
targetting the use of family-based therapies (FBT) and another the prescription of atypical
antipsychotics (olanzapine) in eating disorders. In both cases, I am interested in the effect
these conferences have on individual therapist experimentation; I therefore measure short-
term responses to a conference by the likelihood of utilizing an innovation in the first 6
months following the event.
The main results of the event study on FBT takeup can be seen in Figure 4. The point
estimates suggest that in the month following conference attendance, FBT techniques were
about 8 percentage points more likely to be employed. However, large bootstrapped standard
errors and large pre-trend effects suggest that this result is more attributable to sampling
variation than a true therapist response. Even if there is a short-term response, it quickly
diminishes in the subsequent periods, suggesting a short period of experimentation without
true adoption. As I will discuss in Section 4.1, this result is robust to multiple specifications.
A similar result holds for olanzapine prescriptions, as seen in Figure 5. The estimated
coefficients for this treatment effect are much smaller, with at most a 0.4 percentage point
increase in prescriptions after conference attendance. Overall, the results suggest little, if any,
change in prescribing behavior. The fact that this response is less dramatic than responses
to FBT is somewhat surprising, given my hypothesis about innovation types. I will discuss
potential interpretation of these results in Section 6.
4.1 Robustness
The main results shown above are robust to multiple expressions of the regression specifi-
cation. In particular, I compared results with binary and continuous dependent variables,
the use of all prescriptions (compared to only olanzapine prescriptions), and the decision
of whether to normalize the travel costs by specialist salary (as discussed in Appendix B).
Figures showing how the estimated coefficients changed based on these varying approaches
can be found in Appendix C.
In addition to these typical robustness checks, I also assessed how the results changed rel-
ative to my specification for the two mis-measured treatments. My specification uses cutoff
thresholds in travel costs to assign treatment status to specialists; however, as discussed in
16See Kapetanios (2008) for an excellent review of this procedure.
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Figure 4
Therapist Response to Family-Based Therapy Conferences
Section 3.3.2, there is a tradeoff between satisfying the conditions of Assumption 3 and max-
imizing their correlation with the true treatment status (e.g., mitigating concerns of a weak
instrument problem). I therefore repeat the estimation procedure using various treatment
thresholds, which can also be viewed in Appendix C. The results are quite consistent—if
anything, models estimated with more stringent treatment thresholds (smaller η) appear to
detect larger estimates, but have larger standard errors as well. While future work may
elaborate on the optimal decision of treatment threshold to balance the trade off inherent in
its selection, this figure provides sufficient evidence that the choice of threshold contributes
little to the overall result.
4.2 Heterogeneous Responses by Patient Age
While the overall results show little specialist response to professional conferences—whether
targetting algorithmic or intangible innovations—a null result may mask interesting hetero-
geneous responses. To that end, I investigate potentially differentiated responses by patient
and specialist type. First, specialists may respond to professional conferences selectively,
choosing to implement new techniques on a subset of their patient pool. Particularly, family-
based therapies have been shown to be more effective for adolescents and children, for whom
family structure is a more integral social context (Couturier et al., 2013). On the other hand,
pharmacological interventions may appear more tolerable for adult patients, especially those
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Figure 5
Prescriber Response to Olanzapine Conferences
for whom FBT is not a viable option.
To explore potential heterogeneity along this dimension, I re-estimate the results on the
subset of patients who are under 20 years old. Figures 6 and 7 show the results for the
effect of FBT and olanzapine professional conferences on treatment profiles for youth and
adolescents. The results for FBT use—a treatment which should ostensibly be easier to
implement among adolescents and youth—are practically identical to those shown in Figure
4; however, the results for olanzapine use suggest a small, but more significant, increase
in prescriptions for youth following pharmacological conferences. This suggests a certain
degree of differentiated response among practitioners based on the type of patients they see,
although not in the way one would generally hypothesize.
4.3 Heterogeneous Responses by Specialist Type
In addition to potentially heterogeneous response by patient types, specialists themselves
may differ in their responses to professional conferences. For example, specialists who
hail from a more academic background (e.g., psychologists) may place a higher priority
on evidence-based treatments, and may therefore be more likely to integrate FBT or olan-
zapine into their treatment profiles. To examine this question, I estimate an extended ESIV
model using the D-LATE procedure, including interaction terms for specialist types. That
is, I examine the specification in Equation 6:
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Figure 6
Therapist Response to Family-Based Therapy Conferences Among Patients Under 20
yit = αi + τt + ~γT t + ~δ (T t × si) + εit, (6)
where T t is the vector of relative time dummies used in the event study and si are the
relevant specialty types examined in the regression. Then, the coefficients of interest are
contained in the vector ~δ. Recent papers such as Johannesen and Stolper (2017) have used
this approach as a simple way to explore potential heterogeneous treatment effects.17
To examine heterogeneous takeup of FBT, I compare psychologists and therapists to
other mental health clinicians (family practice doctors, mental health facilities professionals,
etc.); for olanzapine prescriptions, I compare psychiatrists to non mental-health prescribers
(e.g., family practice doctors). Figure 8 shows the differentiated response for FBT takeup,
while Figure 9 shows the same for prescribing. In each figure, the first panel illustrates the
overall dynamic treatment effect (the vector γ in Equation 6), while the other panels are the
relevant parts of the δ vector for each specialist type—therefore, these panels are interpreted
as the relative differences in dynamic treatment effects for each group.18 Psychologists in
17Notice that it isn’t necessary to include level effects for each specialist type si ∈ si, as these will be
picked up by individual fixed effects (for the large majority of the individuals in the sample who don’t switch
provider types).
18If one wanted to construct the dynamic treatment effect for psychologists, say, one would add the γ
vector to the δpsych vector. The standard errors would stay the same as those around δpsych,t for all points
as this they are bootstrapped standard errors, which do not change under a linear shift.
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Figure 7
Prescriber Response to Olanzapine Conferences Among Patients Under 20
general appear to have a much higher fluctuation in the use of family-based therapy, but
tend to use it overall more than their counterparts. The point estimates suggest a higher
positive reaction to the use of FBT for them, but the pre-trends and large standard errors
prevent any definitive conclusions. Other mental health professionals (including therapists)
appear to have a more subdued response to professional conferences on family therapies.
The results for heterogeneity among prescribers are equally interesting. These estimates
have greater power issues than others in this paper due to a smaller group of treated physi-
cians. However, there is still a clear heterogeneous response among prescribers: mental health
professionals who are not psychiatrists tend to respond positively to these conferences, with
a small but significant (and lasting) increase in olanzapine prescriptions following the confer-
ence. Other prescribers show a less noticeable change in behavior; general practitioners do
not respond at all, and psychiatrists respond for only a few periods following the conference.
It may be that psychiatrists are better trained in understanding the risks of a pharmaco-
logical approach, or they may have more of an availability to engage in a psychotherapeutic
intervention than another mental health prescriber (e.g., a psychiatric nurse practitioner).
To the extent that either of these are true, professional conferences may reach those who
have less time for therapeutic responses, a higher tolerance for pharmacological risk, or both.
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Figure 8
Professional Response to Family-Based Therapy Conferences by Specialty
4.4 Experimentation as a Possible Mechanism
Overall, the results suggest a limited and short-lived response to professional conferences.
One potential explanation for this fact is that specialists return from conferences and ex-
periment with new techniques, gauging their overall effectiveness and ease of use before
integrating them into their regular treatment profile. But therapists who attempt to incor-
porate FBT, for example, may dislike the increased coordination cost or have a poor first
experience with the treatment, which may lead them to revert to their original treatment
methods.
To test this hypothesis, I explore the effect of these professional conferences on a spe-
cialist’s likelihood to expand their treatment set. I measure this likelihood by computing
each therapist’s Herfindahl-Hirschman index (HHI) of their treatment profile, as measured
by variation in their billed CPT codes. The HHI is calculated for each therapist i in period





where sijt represents the fraction of provider i’s treatments in time period t that are in
the category j. I calculate the HHI using 9 categories, including individual, group, and
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Figure 9
Professional Response to Olanzapine Conferences by Specialty
family therapies amidst pharmacological interventions and other medical and administrative
claims.19
To the extent that different CPT codes perfectly capture differences in utilized treat-
ment,20 this provides one measure of how specialized a therapist’s treatments are. For exam-
ple, if a therapist specializes exclusively in family-based therapies, there will be no variation
in the treatment profile, leading to an HHI of 1; on the other hand, experimentation with
different treatment methods will cause the HHI to decrease.
I re-estimate the dynamic treatment effects for these conferences using the calculated
HHIs as the new dependent variable. That is, I measure to what extent professional confer-
ences induced specialists to expand (or contract) their treatment methods, inducing experi-
mentation or specialization respectively.
Figure 10 shows the effect that FBT conferences have on this measure of specialization.
Again, there are no strong results, although there is a slight increase in specialization at the
time of the conference (potentially lasting for a few periods). This may result from one of
two potential causes: first, the conference itself may impose limitations on a therapist’s time
19For reference, the 9 categories used are individual therapy, group therapy, family therapy, pharmaco-
logical interventions, evaluation and management, intake procedures, general consultations, hospitalization
treatments, and other codes used rarely.
20There has been a recent discussion on how well physicians agree on the relevant CPT codes for given
treatments (Bentley, Wilson, Derwin, Scodellaro, & Jackson, 2002; King, Sharp, & Lipsky, 2001) making
this calculation an imperfect proxy of true specialization. However, I believe that (given the categories I’ve
selected) disagreement about billing will be minimized in this case, thus making this a useful measure.
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for treatment, requiring them to treat only the patients that they are specialized to treat.
Second, it may also be the case that continuing education induces therapists to favor their
own special skill sets more, as they feel more trained to implement their techniques. Either
way, the effects do not suggest an increase in experimentation with new techniques after a
conference, which would be indicated by a negative trend. A similar result for pharmaceutical
conferences is relegated to Appendix C.
5 Travel Cost Validation
Critical to the interpretation of my results is the extent to which the D-LATE estimation
technique approximates the true LATE. That is, I would ideally understand the probabilities
that my treatment/control measures satisfy the conditions in Assumption 3. While I cannot
verify this in my sample given the unobservability of true treatment, I have obtained a
validation sample of conferences from the Academy of Eating Disorders; this will allow me
to obtain a sense of how well these assumptions might be satisfied in my main data.
For now, I have access to registration for the 2019 ICED Conference held in New York
City, NY.21 That is, I have records of each of the 612 unique US-based organizations which
sent professionals to the conference, as well as their geocoded locations. Figure 11 shows
the approximate home location of each attendee, with the conference location shown in red.
Notice that, as expected, a large fraction of attendees live in close geographic proximity to
the conference location. Interestingly, however, those who travel a greater distance to the
conference appear to be based in metropolitan areas, which have greater proximity to an
airport and subsequently lower travel costs.
I link this data to my Marketscan data in order to have some idea of a ”true” treatment
measure relative to a control group. To do so, I identify every therapist in my sample whose
main location is within a 10 mile radius of an ICED attendee location as being “truly”
treated. Next, to get an idea of how correlated my predicted treatment measure is with
actual attendance, I estimate predicted travel costs for each of the therapists in my sample
and the 2019 ICED conference. I then assign treatment groups using the same thresholds
used throughout the paper, so that η ∈ {1, 2, 5, 10, 15}. These are hypothetical, as my
sample does not extend to 2019, but will give an idea of how well the prediction algorithm
does relative to the truth.
First, I verify the conditions listed in Assumption 3, which are sufficient for the D-LATE
estimator to point identify the true LATE. Recall that for the two treatment measures T a
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and T b, one needs to assume that T a never misclassifies the control group, and that T b never
misclassifies the treatment group. The probabilities of these misclassifications (labelled as pa0
and pb1) are identified for each threshold in Table 2 for the unnormed treatment algorithm.
T a Threshold pa0 T
b Threshold pb1
0.01 0.0000 0.99 0.0074
0.02 0.0000 0.98 0.0086
0.05 0.0172 0.95 0.0103
0.10 0.0645 0.90 0.0360
0.15 0.1155 0.85 0.0406
Table 2
Estimated misclassification probabilities using ICED 2019 data (unnormalized)
In general, these misclassification probabilities decrease with η, suggesting that results
using smaller thresholds are closer to the true LATE. In fact, for this particular validation
sample, the probability pa0 decreases to exactly 0 after η < 5, and the corresponding probabil-
ity pb1 decreases to under 1%. This suggests that the conditions in the third assumption are
well approximated in my current sample, especially for the smallest two values of η (which
include my preferred specification of η = 2).
Additionally, identification of the D-LATE estimator depends on a nonzero correlation
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Figure 11
Actual Attendees of the 2019 ICED Conference in New York City, NY
between T i, i ∈ {a, b} and the true treatment status D. That is, the mismeasured treatments
must give some information about true treatment status; without doing so (or with too small
of a correlation), a problem similar to that of weak instruments arises. Although this cannot
be verified in my sample of interest, I can again utilize the verification sample to assess this
correlation. For brevity, the specific correlations are relegated to the Appendix; however,
these correlations are strong for most measures and average around 0.15, suggesting little
concern of weak identification.
5.1 Normed or Unnormed?
My travel cost algorithm assigned artificial treatment status based on two types of travel
costs: a simple monetary measure (unnormed) and one measured in units of hourly salary
(normed by salary). Thus, a simple question is to ask which of these measures best satisfies
the assumptions needed for the D-LATE estimator to be meaningfully interpreted. In con-
trast to Table 2, Table 3 shows the misclassification measures the predicted travel cost for
each therapist as a multiple of their expected hourly salary.
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T a Threshold pa0 T
b Threshold pb1
0.01 0.0004 0.99 0.0149
0.02 0.0062 0.98 0.0257
0.05 0.0315 0.95 0.0389
0.10 0.0645 0.90 0.0691
0.15 0.1019 0.85 0.0915
Table 3
Estimated misclassification probabilities using ICED 2019 data (normalized)
Overall, the algorithm performs significantly more poorly when normalizing by salary
than when using a simple monetary measure. This is additionally advantageous because—as
discussed in Appendix B—the normed travel cost measure appears to over-assign treatment
status to those in the sample who make higher salaries (e.g, psychiatrists and family practice
doctors) over those who stand to benefit the most from the professional conferences (e.g.,
therapists and mental health facility workers). Given both of these results, results using the
non-normalized treatment algorithm should be taken as closer to the true LATE of interest.
6 Discussion & Conclusion
The methodology outlined above and the results arising from its application each have novel
implications. In general, my project identifies ways that researchers can augment limited
data with powerful statistical learning techniques to answer a broader range of questions
than currently accessible, as illustrated by my analysis of professional conferences and mental
health treatment behaviors.
6.1 Potential Uses of Methodology
A strong causal inference project typically requires rich data to be compelling. However, the
set of questions researchers ask far eclipses the amount of adequate data available to them.
The MR-LATE estimator of Calvi et al. (2019), as well as the D-LATE estimator proposed,
discussed, and utilized here, offer ways researchers can incorporate imperfect data into an
analysis without crippling it.
The estimator used in my project allows for the point identification of a dynamic local
average treatment effect (D-LATE) under relatively mild assumptions. Current statistical
learning techniques are more than capable of generating the mismeasured treatment assign-
ments necessary for the estimator, and can use validation samples or other techniques to
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ensure that the assumptions are met at least approximately. Even in cases where the mis-
classification does not satisfy the conditions of Assumption 3, the D-LATE estimator can
be looked at as a method of bias reduction, moving the estimated treatment effects closer to
the truth by taking into account the possibility of misclassification.
This paper utilized a rather simple predictive algorithm to estimate treatment status of
mental health professionals. Future research could integrate more advanced machine learn-
ing models in its place, thereby extending the set of questions the D-LATE estimator can
answer. Additionally, future econometric research may explore the instrumental variables
approach for event studies introduced here, identify more properties of the D-LATE estima-
tor, and discuss how the work of Calvi et al. (2019) extends to other commonly used causal
identification strategies.
6.2 Diffusion of Mental Health Treatments
This paper utilizes the methodology of the D-LATE estimator to allow imperfect data to
shed light on an important problem in the healthcare industry: the diffusion of ideas. By
examining how professionals respond to continuing medical education covering various types
of innovations, I am able to assess to what extent research-to-practice gaps are developing
in mental health treatments.
The results are suggestive that therapists respond more to tangible innovations than to
intangible ones. While there is no discernible response to conferences covering family-based
therapies, there are situations in which providers are seen increasing their prescriptions of
olanzapine following professional conferences on the subject. The identified heterogeneity
discussed in Section 4 corroborates this finding; therapists from strong medical training and
academic backgrounds (e.g., psychiatry and psychology) respond more positively to family-
based therapy, which has a stronger evidence backing, while eschewing the somewhat weaker
development of atypical antipsychotics. Interestingly, this increase in prescriptions occurs
more among the younger patient population, despite the fact that adolescents and youth
stand to gain the most from a family-based treatment approach rather than a pharmacolog-
ical one.
Of course, future research is critical to confirming these findings. A crucial step will
be extending this research beyond the Marketscan data, moving instead towards a holistic
assessment of provider behavior amidst patients of various degrees of insurance coverage.
Additionally, it will be important to gauge therapist response among other demographics,
including experience, academic training, and clinic type. Replicating this project on a richer
data set (such as all-payer claims data) can both confirm the validity of this estimator and
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its findings as well as identify with greater precision the subset of therapists who respond to
professional conferences.
There are important questions outside of this domain that must be answered surrounding
the impact of continuing medical education and research-to-practice gaps. This project
overlooked the role that referring physicians and other members of the treatment team
(e.g., dietitians) play in the decision to incorporate new treatments, either pharmacological
or therapeutic. However, it may well be the case that these sidelined parties can induce
innovation just as well—or better—than a CME program. Additionally, it may be useful
to examine how provider payment mechanisms, network effects, and insurance coverage all
dictate the decision to update or experiment with new treatments.
Finally, additional research may move beyond the communication problem of continuing
medical education and into other frictions that exacerbate research-to-practice gaps. One
might examine how the evolution of academic medical research may have siloed researchers
into their own niche, and how this affects researcher involvement with practitioners at all.
Additionally, projects might assess how researchers respond to other forms of media sur-
rounding new treatments, including research articles and magazines. Finally, it will be
useful to understand how implementing these new techniques affects the ultimate outcome
for patients, especially those being treated by an intangible innovation.
Only by obtaining a more holistic picture of the different frictions and mechanisms can we
hope to catch a glimpse at a solution to effectively incentivizing the diffusion of better mental
health practices. Similarly, recognizing the manifold characteristics of individual innovations
will allow a richer study of the economics of innovation. By doing so, future work can provide
real solutions to gaps between academic research and real-world practice, as well as foster
more efficient channels of communication in a broad spectrum of policy-oriented fields.
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Appendix A: Proof of Theorem 1
Proof of Theorem 1. Suppose that we observe a panel {Yit} of outcomes for individuals
i = 1, 2, ..., N and periods t = 1, 2, ..., T . Additionally, suppose that there is a true binary
treatment status Dit ∈ {0, 1} for all i and t—for consistency with the event study framework,
D = 1 is an absorbing state, so that Dis = 1 implies that Dit = 1 for all t ≥ s. Additionally,
there is a binary instrument Zit ∈ {0, 1} and two mis-measured treatments T a, T b satisfying
Assumptions 1 and 2 above.
The event study is estimated as follows (using the notation from Abraham and Sun
(2018)): for each individual, define the time of first treatment as Ei = min{t : Dit = 1} and
the related treatment-time dummy variables D`it = 1{t − Ei = `}. The regression equation
is as in 2 with D`it in place of the indicator variables.
As the true treatment is unobserved, we are interested in the local cohort-specific ATE
of a transformed regression of T jY on T j for T j ∈ {T a, T b}. That is, we are interested in
the vector ~γ resulting from estimation of:











In moving from a typical panel data analysis to an event study approach, we move from
a single treatment T jit to a vector of dummy variables {T
`,j
it }`. In the setting where the
fully dynamic equation is not estimated, there are L+K dummy variables to be concerned
with (as we drop the period ` = −1 to avoid any collinearity problems). We therefore
similarly expand the set of instruments from Zit to {Z`it}, again of size L + K. This vector
of instrument dummies is created in the same way the vector of treatment dummies, and
described in Section 3.2. By expanding to multiple instruments, however, each coefficient in
a two-stage regression will be given by a weighted average of LATEs, as discussed in Angrist










where the weights βk are in the interval [0, 1] for all k and satisfy
∑
k βk = 1. As in Calvi
et al. (2019), define q = p1


































= E[qY1 + (1− q)Y0|C] (as weights sum to 1).
Hence, for any time period `, Calvi et al.’s Theorem 1 applies. One can therefore use
two mismeasured treatments T a and T b with the same properties as in their paper (so that
pa0 = p
b
1 = 0) and construct the local cohort average treatment effect:
ρ` = E
[
Y ei,t+` − Y ∞i,t+`|Ei = e, C
]
= γ̂a` − γ̂b`
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Appendix B: Details of the Travel Cost Algorithm
The travel cost algorithm is used to infer the earliest date each medical professional was
exposed to a continuing education event targetting either FBT use or drug prescribing in
eating disorder treatments.
The first step in the algorithm is to assign a location to each specialist. While MarketScan
does not have specifically geotagged locations for their physicians, they do have information
on the Metropolitan Statistical Area in which the main enrollee on each insurance plan
resides. Hence, each claim in a physician’s treatment profile is tagged to one of these MSAs.
By taking the bulk of patients seen in a given month and taking a geocentric average of
their home MSAs (taking as each patient’s location the global midpoint of their MSA), I
can assign a specific location to each specialist-month observation. To avoid large errors, I
discard specialist-month observations that treat patients from larger than a 100-mile radius.
Once a specific location has been assigned to a specialist-month, I can compute the
travel costs between therapists and a given conference. The algorithm allows a specialist
to travel to the conference either by car directly, or by any network of flights. To estimate
driving time and costs, I allow for different average driving speeds in urban areas and on
freeways/interstates, and estimate the price of gas using data from the United States Bureau
of Labor Statistics (BLS). To estimate flying time and costs, I incorporate data on airport
locations, flight availability, and airfare from the United States Bureau of Transportation.
Then, I construct a network between a specialist’s origin point (their home location) and
their destination (the conference location) that allows them to (i) drive to any of the 5
airports closest to their home, (ii) take any network of flights from that airport to any of
the 5 airports closest to their destination, and (iii) drive from that airport to the conference
location. Once this network is completed, I assume that travelers will choose the cheapest
option (in terms of both airfare and opportunity cost of travel).
Opportunity cost of time is calculated using BLS wage data. I estimate this opportunity
cost in two ways: assigning each specialist in my data set the same hourly wage (the average
median wage for all specialist groups in the sample), or assigning each specialist group their
own median wage. For example, psychiatrists would be assigned a median wage of $105.95
per hour while mental health clinicians would be assign a median wage of $21.46 per hour.
Under the second method, travel costs are reported as a percentage of each specialist’s
average salary, to keep units consistent.
While there is clearly a large amount of variation in specialist wages, this variation
appears to be negatively correlated with true attendance. That is, those with the lowest
median wages (e.g., treatment center workers, therapists) have a greater incentive to attend
conferences on eating disorder treatments than general practice doctors or psychiatrists,
who treat a larger range of diagnoses. However, when adjusting for different salaries, I am
implicitly making the costs of travel (gas, airfare, etc.) less inhibitive for those with higher
salaries, so the algorithm may be more likely to predict treatment for those who are less
incentivized to truly attend.
As discussed in the paper, once this algorithm is complete, each specialist-conference
pair is assigned a travel cost c ∈ R. For the “unnormalized” option where each specialist is
assigned a flat salary, this is a monetary measure in 2016 U.S. dollars; on the other hand,
when different salaries are assigned to different specialists, this is measured as each specialist’s
39
travel costs in salary hours. From this continuous measure, I form the dichotomous prediction
of treatment and control groups using an artificial cutoff η ∈ [0, 1], where any specialist with
travel cost at or below the value F (η) is considered to have attended the conference.
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Appendix C: Additional Results
As mentioned previously, the results shown in the paper are robust to several iterations of
estimation. I re-estimated the results with a continuous dependent variable instead of a
binary one, and with a travel cost that was normalized to be in terms of each therapist’s
estimated salary (instead of a pure monetary measure). These sensitivity results are shown
in Figure 12 for all 12 regression coefficients of the dynamic treatment effect. Note that
throughout, I include the figures only for family-based therapies; the results are similar for
olanzapine prescriptions.
Additionally, the results are re-estimated with various thresholds used in assigning treat-
ment/control status. Each treatment measure assumes that those therapists with travel costs
in the lowest η-percentile of all travel costs for a given conference attended it, and were thus
treated. Each specification consists of a treatment measure using η as the percentile, and
the other using 1 − η. For example, the specification of choice uses the “strict” treatment
measure as those whose travel costs are in the bottom 2%, while the “liberal” one applies
treatment to those in the bottom 98%. I also test specifications where η ∈ {1, 2, 5, 10, 15}.
The resulting variation in estimated coefficients is illustrated in Figure 13.
The results are generally quite consistent—if anything, models estimated with more strin-
gent treatment thresholds (smaller η) appear to detect larger estimates, but have larger stan-
dard errors as well. While future work may elaborate on the optimal decision of treatment
threshold to balance the trade off inherent in its selection, this figure provides sufficient
evidence that the choice of threshold contributes little to the overall result.
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